Edition:
United Kingdom

Seattle Genetics, Astellas Announce Progress In Enfortumab Vedotin Urothelial Cancer Clinical Development Program


Monday, 9 Jul 2018 

July 9 (Reuters) - Astellas Pharma Inc <4503.T>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE PROGRESS IN ENFORTUMAB VEDOTIN UROTHELIAL CANCER CLINICAL DEVELOPMENT PROGRAM.SEATTLE GENETICS INC - ENROLLMENT OF EV-201 PIVOTAL TRIAL COHORT DESIGNED TO SUPPORT POTENTIAL EXPEDITED REGISTRATION PATHWAY IN U.S. COMPLETED.